Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...
Saved in:
因特网
https://doi.org/10.1371/journal.pone.0231828https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0231828/1/pone.0231828.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210221%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210221T143530Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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